最新！北京国资联合投资，这家清华系AI+合成生物制造企业是做什么的？

Recently, the synthetic biology manufacturing sector announced another major funding round:Beijing Green Chengsheng Biotechnology Co., Ltd. (hereinafter referred to as "Green Chengsheng")Officially completedTens of millions in Pre-A round funding。

This round of financing is led byBeijing State-owned Assets Supervision and Administration Commission's Beijing Green Energy and Low-carbon Industry Investment Fund, Future Science City Group's Beijing Future Star Venture Capital, and Beijing Changjianfa Investment Management CenterJoint investment is a key strategic move by Beijing's municipal and district-level state-owned capital to collaboratively position the future synthetic biology industry.

[From Tsinghua, Rooted in Beijing: Built on Hard-Core Technology]

Green Chengxi was established in Beijing in 2022 and is a national high-tech enterprise derived from core technological achievements transferred from Tsinghua University. The founder and Chief Scientist, Dr. Chen Zhen, is a tenure-track associate professor at Tsinghua University who successfully scaled 1,2-propanediol synthesis biotechnology to million-ton-level industrial production, breaking DuPont's multi-year monopoly. CEO Dr. Chen Jiaqi is a former senior technical and business manager at Shell, with over a decade of hands-on experience commercializing technologies for Fortune Global 500 companies. The core team includes members from top institutions such as Tsinghua University, Peking University, Tokyo Institute of Technology, and the Chinese Academy of Sciences, while the engineering and production teams are composed of seasoned professionals from leading industry players.

Precise market positioningAI + Synthetic Biology ManufacturingGold Track, PositioningInnovative Manufacturer of Health-Active Ingredients and Bio-Based Materials, clear core mission: useSynthetic biology enables green, independent production of key chemicals, breaking through import bottlenecks.。

Since its inception, Green Cheng has rapidly established a technical closed loop and obtained necessary certifications, emerging as a core innovator within Beijing's synthetic biology cluster. This aligns with the national strategic direction for bio-manufacturing in the upcoming 15th Five-Year Plan.

[A Empowerment + Biomanufacturing: Two Core Barriers]

AI-Driven BioDesign: A Quantum Leap in R&D Efficiency

Unlike traditional biomanufacturing companies, Green Chengxin deeply integrates AI technology with synthetic biology to build a proprietary...AI-powered Bio-Design PlatformDesign microbial cell factories with AI to shorten R&D cycles; accurately predict protein structure and function for targeted enzyme optimization; use high-throughput screening to identify top-performing strains and significantly reduce trial-and-error costs.

Synthetic biology "cell factories": green alternatives to imported products

Built on Tsinghua University's technical expertise, our company has developed an efficient microbial fermentation platform focused on two core product lines. We deliver fully green fermentation processes with no heavy metal residues and sustainable mass production, breaking the long-standing monopoly of foreign enterprises in the high-end bioactive ingredient market.

Health & Wellness Active IngredientsHigh-value-added products such as sialic acid, carnosine, and L-histidine—replacing chemical synthesis or natural extraction with significantly reduced costs—are now ready for large-scale production.
Monomers of Bio-based MaterialsBiodegradable materials and green chemical intermediates that support "Dual Carbon" goals and replace petroleum-based products.

From "Tons" to "Thousand-Ton Scale":

Industrialization accelerates.

Synthetic biology, as a key representative of new quality productive forces,Transitioning from the "technical validation phase" to the "industrialization realization phase." 。

To support rapid production line scaling, Green Chengcheng has completed its first industrial demonstration platform in Xinbei District, Changzhou, and2025-5 officially launchedAchieved stable mass production and ton-scale flexible manufacturing for multiple high-value small-molecule raw materials. This funding round will accelerate process scale-up and capacity expansion for high-value product pipelines, advance international certification of core raw materials, drive global market expansion, and initiate pre-engineering for next-generation large-scale production lines.

More importantly, this round of joint investment by Beijing's state-owned capital system not only recognizes Green Cheng's technical capabilities but also reflects the forward-looking strategic layout of state-owned capital in the green bio-manufacturing sector under the "Dual Carbon" strategy.

InNational strategy sets the tone, capital continues to pour in, and technology unfolds across multiple fronts."During a transformative period for the biomanufacturing industry, Green Cheng is charting a high-quality path from lab to commercialization. Led by a core team of top-tier scientists and powered by an AI-driven end-to-end R&D platform, the company has made deep strategic investments in two golden sectors: nutritional health and bio-based materials."

2026 (2nd) EMBC Bio-Manufacturing Industry Conference & Exhibition (Summer)

2026 (2nd) EMBC Bio-Manufacturing Industry Conference & Exhibition (Summer)will be8 27-28Held in Shanghai, the exhibition will invite2000+ Attendees,100+Speaker,20+Premium exhibitors, featuring "Exhibitions - Products - Conferences - PartnershipsFour core modules focused on "breakthroughs in fundamental research + cross-domain industrial implementation."

Whether you are an entrepreneur, investor, technical expert, or procurement decision-maker in the bio-manufacturing sector, this exhibition offers a platform to explore the latest policy trends and industry developments, connect with top-tier capital and high-quality projects, and showcase cutting-edge technologies and innovative products.